305 related articles for article (PubMed ID: 30626425)
21. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
22. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma.
Scudla V; Pika T; Budikova M; Petrova J; Minarik J; Bacovsky J; Langova K; Zivna J;
Neoplasma; 2010; 57(2):102-10. PubMed ID: 20099972
[TBL] [Abstract][Full Text] [Related]
23. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density.
Alexandrakis MG; Passam FH; Pappa CA; Damilakis J; Tsirakis G; Kandidaki E; Passam AM; Stathopoulos EN; Kyriakou DS
Int J Immunopathol Pharmacol; 2005; 18(2):287-95. PubMed ID: 15888251
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
[TBL] [Abstract][Full Text] [Related]
26. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
[TBL] [Abstract][Full Text] [Related]
27. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy.
Ria R; Portaluri M; Russo F; Cirulli T; Di Pietro G; Bambace S; Cucci F; Romano T; Vacca A; Dammacco F
Cancer Lett; 2004 Dec; 216(1):103-7. PubMed ID: 15500953
[TBL] [Abstract][Full Text] [Related]
29. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
30. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.
Heeschen C; Dimmeler S; Hamm CW; Boersma E; Zeiher AM; Simoons ML;
Circulation; 2003 Feb; 107(4):524-30. PubMed ID: 12566361
[TBL] [Abstract][Full Text] [Related]
32. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
33. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
Ludek P; Hana S; Zdenek A; Martina A; Dana K; Tomas B; Lucie K; Marta K; Jaroslav M; Miroslav P; Jiri V; Roman H
Eur J Haematol; 2010 Apr; 84(4):332-6. PubMed ID: 20015241
[TBL] [Abstract][Full Text] [Related]
34. Investigating the role of angiogenesis in systemic lupus erythematosus.
Liu J; Wang X; Yang X; Yan Q; Wang S; Han W
Lupus; 2015 May; 24(6):621-7. PubMed ID: 25359881
[TBL] [Abstract][Full Text] [Related]
35. [Anti-angiogenesis effect of metronomic chemotherapy in multiple myeloma patients].
Guo LP; Zhou F; Wei W; Zhang YZ; Shi HT; Lin CH; Li L; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):457-60. PubMed ID: 22967380
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of angiopoietin-2 in multiple myeloma.
Pappa CA; Alexandrakis MG; Boula A; Thanasia A; Konsolas I; Alegakis A; Tsirakis G
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1801-5. PubMed ID: 24906877
[TBL] [Abstract][Full Text] [Related]
37. Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.
Alexandrakis MG; Pappa CA; Kokonozaki M; Boula A; Vyzoukaki R; Staphylaki D; Papadopoulou A; Androulakis N; Tsirakis G; Sfiridaki A
Med Oncol; 2015 Mar; 32(3):42. PubMed ID: 25631632
[TBL] [Abstract][Full Text] [Related]
38. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
[TBL] [Abstract][Full Text] [Related]
39. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
40. [Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas].
Poreba M; Jaźwiec B; Kuliczkowski K; Poreba R
Pol Arch Med Wewn; 2005 Jan; 113(1):27-34. PubMed ID: 16130598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
